TaiGen Biotechnology

Company

Last mentioned: Mar 6, 2026

Timeline

  1. Phase I Milestone

    First human subject enrolled and dosed in the Phase I clinical trial.

  2. AI Discovery

    Insilico Medicine identifies ISM4808 using its Pharma.AI platform.

  3. Out-Licensing

    TaiGen Biotechnology secures rights for the clinical development of the candidate.

Stories mentioning TaiGen Biotechnology 1

health-it Bullish

Insilico and TaiGen Advance AI-Derived CKD Anemia Drug to Phase I Trials

Insilico Medicine and TaiGen have successfully enrolled and dosed the first human subject in a Phase I clinical trial for ISM4808, a novel drug candidate for Chronic Kidney Disease (CKD) anemia. The milestone validates the clinical transition of an AI-discovered molecule under a strategic out-licensing agreement.

3 sources